Stockscreener 앱 받기
51.84
2.49%
1.26
Akero Therapeutics Inc 주식(AKRO)의 최신 뉴스
10 Best Performing Pharma Stocks So Far in 2025 - Insider Monkey
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 10,000 Shares of Stock - MarketBeat
Akero Therapeutics chief development officer sells $498k in stock By Investing.com - Investing.com Australia
Akero Therapeutics chief development officer sells $498k in stock - Investing.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Growth in Short Interest - MarketBeat
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Grabar Law Office is Investigating Claims on Behalf of - GlobeNewswire
Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino’s Pizza Corp. (NASDAQ: DPZ) - TradingView
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
10 Best Performing Healthcare Stocks So Far in 2025 - Insider Monkey
Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025 - Insider Monkey
Akero Therapeutics' chief scientific officer sells $1.74 million in stock - MSN
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $75.86 Average PT from Brokerages - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Large Increase in Short Interest - Defense World
Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Target Price at $75.86 - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 Shares - MarketBeat
(AKRO) Technical Pivots with Risk Controls - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect - Markets Insider
Is Akero Therapeutics Inc (NASDAQ: AKRO) A Good Pick For New Investors Now? - Stocks Register
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by abrdn plc - MarketBeat
Akero Therapeutics director Graham Walmsley acquires $9.6 million in stock - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - Markets Insider
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 18,750 Shares - MarketBeat
Akero Therapeutics Insider Sold Shares Worth $1,581,994, According to a Recent SEC Filing - Marketscreener.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Director G. Walmsley Graham Acquires 200,000 Shares - MarketBeat
Akero Therapeutics CEO Cheng Andrew Sells 30,000 Shares - TradingView
Investigation announced for Long-Term Investors in shares - openPR
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Financial Analysis: Akero Therapeutics Inc (AKRO)’s Ratios Unveil Key Insights - The Dwinnex
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - Markets Insider
Akero Therapeutics' chief scientific officer sells $1.06 million in stock - MSN
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Akero Therapeutics COO Jonathan Young sells shares worth $538,060 - MSN
Jonathan Young Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
This Stock Just Doubled in 1 Day -- Is It Still a Buy? - AOL
Akero Therapeutics' chief scientific officer sells $1.06 million in stock By Investing.com - Investing.com South Africa
Akero Therapeutics’ chief scientific officer sells $1.06 million in stock By Investing.com - Investing.com Nigeria
Akero Therapeutics Stock Doubles on Liver Data - MSN
Akero Therapeutics director Graham Walmsley acquires $9.6 million in stock By Investing.com - Investing.com Australia
0.27%
3.05%
자본화:
|
볼륨(24시간):